434 related articles for article (PubMed ID: 22479182)
1. A cytoplasmic tail determinant in HIV-1 Vpu mediates targeting of tetherin for endosomal degradation and counteracts interferon-induced restriction.
Kueck T; Neil SJ
PLoS Pathog; 2012; 8(3):e1002609. PubMed ID: 22479182
[TBL] [Abstract][Full Text] [Related]
2. Vpu downmodulates two distinct targets, tetherin and gibbon ape leukemia virus envelope, through shared features in the Vpu cytoplasmic tail.
Lucas TM; Janaka SK; Stephens EB; Johnson MC
PLoS One; 2012; 7(12):e51741. PubMed ID: 23284757
[TBL] [Abstract][Full Text] [Related]
3. HIV-1 Vpu Antagonizes CD317/Tetherin by Adaptor Protein-1-Mediated Exclusion from Virus Assembly Sites.
Pujol FM; Laketa V; Schmidt F; Mukenhirn M; Müller B; Boulant S; Grimm D; Keppler OT; Fackler OT
J Virol; 2016 Aug; 90(15):6709-6723. PubMed ID: 27170757
[TBL] [Abstract][Full Text] [Related]
4. Serine Phosphorylation of HIV-1 Vpu and Its Binding to Tetherin Regulates Interaction with Clathrin Adaptors.
Kueck T; Foster TL; Weinelt J; Sumner JC; Pickering S; Neil SJ
PLoS Pathog; 2015 Aug; 11(8):e1005141. PubMed ID: 26317613
[TBL] [Abstract][Full Text] [Related]
5. β-TrCP is dispensable for Vpu's ability to overcome the CD317/Tetherin-imposed restriction to HIV-1 release.
Tervo HM; Homann S; Ambiel I; Fritz JV; Fackler OT; Keppler OT
Retrovirology; 2011 Feb; 8():9. PubMed ID: 21310048
[TBL] [Abstract][Full Text] [Related]
6. HIV-1 Vpu neutralizes the antiviral factor Tetherin/BST-2 by binding it and directing its beta-TrCP2-dependent degradation.
Mangeat B; Gers-Huber G; Lehmann M; Zufferey M; Luban J; Piguet V
PLoS Pathog; 2009 Sep; 5(9):e1000574. PubMed ID: 19730691
[TBL] [Abstract][Full Text] [Related]
7. Vpu binds directly to tetherin and displaces it from nascent virions.
McNatt MW; Zang T; Bieniasz PD
PLoS Pathog; 2013; 9(4):e1003299. PubMed ID: 23633949
[TBL] [Abstract][Full Text] [Related]
8. Contribution of the Cytoplasmic Determinants of Vpu to the Expansion of Virus-Containing Compartments in HIV-1-Infected Macrophages.
Leymarie O; Lepont L; Versapuech M; Judith D; Abelanet S; Janvier K; Berlioz-Torrent C
J Virol; 2019 Jun; 93(11):. PubMed ID: 30867316
[TBL] [Abstract][Full Text] [Related]
9. Antagonism of tetherin restriction of HIV-1 release by Vpu involves binding and sequestration of the restriction factor in a perinuclear compartment.
Dubé M; Roy BB; Guiot-Guillain P; Binette J; Mercier J; Chiasson A; Cohen EA
PLoS Pathog; 2010 Apr; 6(4):e1000856. PubMed ID: 20386718
[TBL] [Abstract][Full Text] [Related]
10. The ESCRT-0 component HRS is required for HIV-1 Vpu-mediated BST-2/tetherin down-regulation.
Janvier K; Pelchen-Matthews A; Renaud JB; Caillet M; Marsh M; Berlioz-Torrent C
PLoS Pathog; 2011 Feb; 7(2):e1001265. PubMed ID: 21304933
[TBL] [Abstract][Full Text] [Related]
11. The C-Terminal End of HIV-1 Vpu Has a Clade-Specific Determinant That Antagonizes BST-2 and Facilitates Virion Release.
Sharma S; Jafari M; Bangar A; William K; Guatelli J; Lewinski MK
J Virol; 2019 Jun; 93(11):. PubMed ID: 30867310
[TBL] [Abstract][Full Text] [Related]
12. Vpu-Mediated Counteraction of Tetherin Is a Major Determinant of HIV-1 Interferon Resistance.
Kmiec D; Iyer SS; Stürzel CM; Sauter D; Hahn BH; Kirchhoff F
mBio; 2016 Aug; 7(4):. PubMed ID: 27531907
[TBL] [Abstract][Full Text] [Related]
13. Vpu antagonizes BST-2-mediated restriction of HIV-1 release via beta-TrCP and endo-lysosomal trafficking.
Mitchell RS; Katsura C; Skasko MA; Fitzpatrick K; Lau D; Ruiz A; Stephens EB; Margottin-Goguet F; Benarous R; Guatelli JC
PLoS Pathog; 2009 May; 5(5):e1000450. PubMed ID: 19478868
[TBL] [Abstract][Full Text] [Related]
14. The RING-CH ligase K5 antagonizes restriction of KSHV and HIV-1 particle release by mediating ubiquitin-dependent endosomal degradation of tetherin.
Pardieu C; Vigan R; Wilson SJ; Calvi A; Zang T; Bieniasz P; Kellam P; Towers GJ; Neil SJ
PLoS Pathog; 2010 Apr; 6(4):e1000843. PubMed ID: 20419159
[TBL] [Abstract][Full Text] [Related]
15. Expression of HIV-1 Vpu leads to loss of the viral restriction factor CD317/Tetherin from lipid rafts and its enhanced lysosomal degradation.
Rollason R; Dunstan K; Billcliff PG; Bishop P; Gleeson P; Wise H; Digard P; Banting G
PLoS One; 2013; 8(9):e75680. PubMed ID: 24086611
[TBL] [Abstract][Full Text] [Related]
16. Role of the endocytic pathway in the counteraction of BST-2 by human lentiviral pathogens.
Lau D; Kwan W; Guatelli J
J Virol; 2011 Oct; 85(19):9834-46. PubMed ID: 21813615
[TBL] [Abstract][Full Text] [Related]
17. Vpu directs the degradation of the human immunodeficiency virus restriction factor BST-2/Tetherin via a {beta}TrCP-dependent mechanism.
Douglas JL; Viswanathan K; McCarroll MN; Gustin JK; Früh K; Moses AV
J Virol; 2009 Aug; 83(16):7931-47. PubMed ID: 19515779
[TBL] [Abstract][Full Text] [Related]
18. Structural basis of HIV-1 Vpu-mediated BST2 antagonism via hijacking of the clathrin adaptor protein complex 1.
Jia X; Weber E; Tokarev A; Lewinski M; Rizk M; Suarez M; Guatelli J; Xiong Y
Elife; 2014 Apr; 3():e02362. PubMed ID: 24843023
[TBL] [Abstract][Full Text] [Related]
19. Suppression of Tetherin-restricting activity upon human immunodeficiency virus type 1 particle release correlates with localization of Vpu in the trans-Golgi network.
Dubé M; Roy BB; Guiot-Guillain P; Mercier J; Binette J; Leung G; Cohen EA
J Virol; 2009 May; 83(9):4574-90. PubMed ID: 19244337
[TBL] [Abstract][Full Text] [Related]
20. Polarity changes in the transmembrane domain core of HIV-1 Vpu inhibits its anti-tetherin activity.
Lv M; Wang J; Wang X; Zuo T; Zhu Y; Kong W; Yu X
PLoS One; 2011; 6(6):e20890. PubMed ID: 21674066
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]